Bittium Corporation
Press Release

Bittium's Analyst Coverage Expands

Bittium Corporation, Press Release on 6 November 2025 at 9:30 am (CET+1)

Bittium Corporation has signed an analyst coverage agreement with the German broker NuWays AG. NuWays offers investors free equity research on selected German and European small and mid-cap listed companies. Bittium’s analyst in NuWays’ team is Julius Neittamo. NuWays’ first report on Bittium has been published today at https://www.nuways-ag.com/company/bittium-oyj.

“Bittium’s strategic goal is to accelerate international growth. As the interest towards company’s share has increased across the Europe, we have decided to expand our analyst coverage to serve both domestic and international investors even better,” says Petri Toljamo, President and CEO of Bittium Corporation.

Bittium's share is also monitored by OP (Osuuspankki) and Inderes. More information about Bittium's analysts is available at www.bittium.com/investors/shares-and-shareholders/analysts. Forecasts and analyses are the independent and unbiased views of analysts. Bittium has no influence on the content of the analyses or the reliability of the information presented in them. The information on this page should not be considered investment advice.
 

Further information:

Karoliina Malmi
Vice President, Communications and Sustainability
Email: karoliina.malmi(a)bittium.com
Tel. +358 40 344 2789

Distribution:

Main media

Bittium

Bittium specializes in the development of reliable, secure communications and connectivity solutions leveraging its 40-year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, customized solutions based on its product platforms and R&D services. Complementing its communications and connectivity solutions, Bittium offers proven information security solutions for mobile devices and portable computers. Bittium also provides healthcare technology products and services for biosignal measuring in the areas of cardiology and neurophysiology. Net sales in 2024 were EUR 85.2 million and operating profit EUR 8.6 million. Bittium is listed on Nasdaq Helsinki. www.bittium.com

Files
Bittium's Analyst Coverage Expands (wkr0006.pdf)